DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.
Momeny M, Tienhaara M, Sharma M, Chakroborty D, Varjus R, Takala I, Merisaari J, Padzik A, Vogt A, Paatero I, Elenius K, Laajala TD, Kurppa KJ, Westermarck J.
Momeny M, et al. Among authors: elenius k.
EMBO Mol Med. 2024 Jul;16(7):1603-1629. doi: 10.1038/s44321-024-00088-0. Epub 2024 Jun 17.
EMBO Mol Med. 2024.
PMID: 38886591
Free PMC article.